{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:39:23Z","timestamp":1788399563655,"version":"build-2803163510"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,28]]},"DOI":"10.18632\/oncotarget.9642","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T23:02:28Z","timestamp":1464303748000},"page":"40518-40530","source":"Crossref","is-referenced-by-count":18,"title":["A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation"],"prefix":"10.18632","volume":"7","author":[{"given":"Peter E.","family":"Ghaly","sequence":"first","affiliation":[{"name":"Department of Chemistry, University of Alberta, Edmonton, AB T6G 2G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab M.","family":"Abou El-Magd","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Genetic Engineering and Biotechnology Institute, City of Scientific Research and Technological Application, New Borg El-Arab City, Alexandria, 21934, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra D. M.","family":"Churchill","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Alberta, Edmonton, AB T6G 2G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A.","family":"Tuszynski","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Department of Physics, University of Alberta, Edmonton, AB T6G 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. G.","family":"West","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Alberta, Edmonton, AB T6G 2G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"1","first-page":"275","article-title":"Observations sur le m\u00e9moire de M. Sertuerner relatif \u00e0 l'analyse de l'opium","volume":"12","author":"Robiquet","year":"1817","journal-title":"Ann Chim Phys"},{"key":"2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0041-008X(61)90013-8","article-title":"Toxicity studies on noscapine","volume":"3","author":"Flataker","year":"1961","journal-title":"Toxicol Appl Pharmacol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1073\/pnas.95.4.1601","article-title":"Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells","volume":"95","author":"Joshi","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002620000109","article-title":"Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses","volume":"49","author":"Kapp","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"5","doi-asserted-by":"crossref","first-page":"17200","DOI":"10.1074\/jbc.M110369200","article-title":"Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint","volume":"277","author":"Joshi","year":"2002","journal-title":"J Biol Chem"},{"key":"6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00280-007-0430-y","article-title":"Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent","volume":"60","author":"Joshi","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/CAD.0b013e3282eea257","article-title":"Apoptotic pathway induced by noscapine in human myelogenous leukemic cells","volume":"18","author":"Mahmoudian","year":"2007","journal-title":"Anticancer Drugs"},{"key":"8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-010-1356-3","article-title":"Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo","volume":"67","author":"Dong","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbrc.2012.04.079","article-title":"Noscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitro","volume":"421","author":"Dong","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/CAD.0b013e3282ffd68d","article-title":"Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway","volume":"19","author":"Zagzag","year":"2008","journal-title":"Anticancer Drugs"},{"key":"11","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1016\/j.bmc.2006.05.069","article-title":"Synthesis and in vitro cytotoxicity of haloderivatives of noscapine","volume":"14","author":"Chandra","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10822-011-9430-4","article-title":"Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid","volume":"25","author":"Joshi","year":"2011","journal-title":"J Comput Aided Mol Des"},{"key":"13","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1124\/mol.105.021899","article-title":"Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma","volume":"69","author":"Joshi","year":"2006","journal-title":"Mol Pharmacol"},{"key":"14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/1087057111418654","article-title":"Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids","volume":"16","author":"Joshi","year":"2011","journal-title":"J Biomol Screen"},{"key":"15","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1016\/j.bmc.2006.09.012","article-title":"Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog","volume":"14","author":"Joshi","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bcp.2011.03.029","article-title":"Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation","volume":"82","author":"Aneja","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"17","doi-asserted-by":"crossref","first-page":"e77970","DOI":"10.1371\/journal.pone.0077970","article-title":"Rational design, synthesis, and biological evaluation of third generation \u03b1-noscapine analogues as potent tubulin binding anti-cancer agents","volume":"8","author":"Kantevari","year":"2013","journal-title":"PLoS One"},{"key":"18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0165-6147(03)00161-5","article-title":"Microtubule-interacting drugs for cancer treatment","volume":"24","author":"Joshi","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1039\/C3NP70092E","article-title":"Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities","volume":"31","author":"Mooberry","year":"2014","journal-title":"Nat Prod Rep"},{"key":"20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.chembiol.2013.01.014","article-title":"The binding sites of microtubule-stabilizing agents","volume":"20","author":"Miller","year":"2013","journal-title":"Chem Biol"},{"key":"21","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","article-title":"An overview of tubulin inhibitors that interact with the colchicine binding site","volume":"29","author":"Miller","year":"2012","journal-title":"Pharm Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jmgm.2011.03.004","article-title":"Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site","volume":"29","author":"Joshi","year":"2011","journal-title":"J Mol Graph Model"},{"key":"23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/mol.63.4.799","article-title":"Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation","volume":"63","author":"Joshi","year":"2003","journal-title":"Mol Pharmacol"},{"key":"24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1747-0285.2011.01189.x","article-title":"Determination of noscapine's localization and interaction with the tubulin-\u03b1\/\u03b2 heterodimer","volume":"78","author":"Tuszynski","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"25","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1021\/jo01056a064","article-title":"Some Substitution Reactions of Isovanillin and Related Compounds","volume":"27","author":"Brotherton","year":"1962","journal-title":"J Org Chem"},{"key":"26","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/jo00162a011","article-title":"General method for the synthesis of phthalaldehydic acids and phthalides from o-bromobenzaldehydes via ortho-lithiated aminoalkoxides","volume":"48","author":"Borchardt","year":"1983","journal-title":"J Org Chem"},{"key":"27","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.tet.2006.02.015","article-title":"Synthesis of cicerfuran, an antifungal benzofuran, and some related analogues","volume":"62","author":"Hall","year":"2006","journal-title":"Tetrahedron"},{"key":"28","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1039\/c2ob25409c","article-title":"CN-assisted oxidative cyclization of cyano cinnamates and styrene derivatives: a facile entry to 3-substituted chiral phthalides","volume":"10","author":"Sudalai","year":"2012","journal-title":"Org Biomol Chem"},{"key":"29","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1002\/chem.201200039","article-title":"Aromatic-amide-derived olefins as a springboard: isomerization-initiated palladium-catalyzed hydrogenation of olefins and reductive decarbonylation of acyl chlorides with hydrosilane","volume":"18","author":"Shang","year":"2012","journal-title":"Chem. Eur. J"},{"key":"30","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1088\/0957-4484\/17\/4\/014","article-title":"Comparative modelling of human \u03b2 tubulin isotypes and implications for drug binding","volume":"17","author":"Tuszynski","year":"2006","journal-title":"Nanotechnology"},{"key":"31","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Folkman","year":"2000","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"10183","DOI":"10.1158\/0008-5472.CAN-05-2002","article-title":"Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1","volume":"65","author":"Rebbaa","year":"2005","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jmb.2014.02.005","article-title":"The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization","volume":"426","author":"Steinmetz","year":"2014","journal-title":"J Mol Biol"},{"key":"34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Knossow","year":"2004","journal-title":"Nature"},{"key":"35","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1021\/jm050502t","article-title":"A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach","volume":"48","author":"Gussio","year":"2005","journal-title":"J Med Chem"},{"key":"36","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1021\/bi300474q","article-title":"Discrimination of ligands with different flexibilities resulting from the plasticity of the binding site in tubulin","volume":"51","author":"Bhattacharyya","year":"2012","journal-title":"Biochemistry"},{"key":"37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bmc.2011.11.010","article-title":"Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1","volume":"20","author":"Hansen","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"38","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1016\/j.bmc.2009.09.044","article-title":"Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones","volume":"17","author":"Lawrence","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/med.20097","article-title":"Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin","volume":"28","author":"Banerjee","year":"2008","journal-title":"Med Res Rev"},{"key":"40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/157489209787002524","article-title":"The anti-cancer activity of noscapine: a review","volume":"4","author":"Rahimi-Moghaddam","year":"2009","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"41","unstructured":"ClinicalTrials.gov. A Study of Noscapine HCl (CB3304) in Patients With Relapsed or Refractory Multiple Myeloma: https:\/\/clinicaltrials\/gov\/ct2\/show\/record\/NCT00912899, (accessed September 23, 2015)."},{"key":"42","first-page":"399","article-title":"Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model","volume":"30","author":"Rogosnitzky","year":"2010","journal-title":"Anticancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.bcp.2004.08.032","article-title":"Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012","volume":"68","author":"Joshi","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-004-0903-1","article-title":"EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice","volume":"55","author":"Joshi","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cbdd.12132","article-title":"Experimental and computational study of the interaction of novel colchicinoids with a recombinant human \u03b1I\/\u03b2I-tubulin heterodimer","volume":"82","author":"Tuszynski","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.molstruc.2011.05.023","article-title":"Fluorescence quenching and ligand binding: A critical discussion of a popular methodology","volume":"998","author":"Stella","year":"2011","journal-title":"J Mol Struct"},{"key":"47","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3061-6","volume-title":"Principles of fluorescence spectroscopy","author":"Lakowicz","year":"1999"},{"key":"48","volume-title":"Drug Resistance in Breast Cancer: Characterization of Rationally Designed Paclitaxel Analogs in Model Systems","author":"St.George","year":"2013"},{"key":"49","volume-title":"In AMBER 2015","author":"Homeyer","year":"2015"},{"key":"50","unstructured":"Chemical Computing Group Inc. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2013.08."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:13:17Z","timestamp":1594829597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":50,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6,28]]}},"alternative-id":["9642","27777381"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9642","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}